Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion Healthcare IPO To Accelerate Celltrion's Global Biosimilar Expansion

Executive Summary

Celltrion Healthcare's initial public offering, which is seen as the most anticipated biotech IPO in South Korea's Kosdaq market this year, is set to speed up Celltrion's expansion of its global market presence as well as the development of biosimilars and novel drugs.

Advertisement

Related Content

AbClon Shines On Korean Debut Amid Robust Investor Interest
Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results
Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
Celltrion Healthcare IPO Set To Benefit From Biosimilar Successes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel